AIM ImmunoTech Inc.
AIM- Exchange
- NYSE
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0000946644
In the last 90 days, AIM ImmunoTech Inc. insiders filed 4 open-market purchases and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $325.6K in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding AIM ImmunoTech Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 39 | 36 | −3 |
| Shares | 5.36M | 4.76M | −600.8K (−11.2%) |
| Value | $1.67M | $2.05M | +$377.1K (+22.6%) |
New holders (1)
Institutions that held AIM ImmunoTech Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Captrust Financial Advisors | 20,000 | $8.60K | 0.00% |
Sold out (4)
Institutions that held AIM ImmunoTech Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Raymond James Financial Services Advisors, Inc. | 36,950 | $11.5K |
| Virtu Financial LLC | 32,088 | $10.0K |
| Millennium Management LLC | 18,191 | $6.00K |
| Credit Suisse AG | 9 | $3 |